1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
62E331EBC0E2D47A100258601003124B4
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-best-practices-use-of-digital-technologies-within-medical-affairs-patient-engagement-emerging-trends?opendocument
18
19opendocument
203.237.66.86
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Digital Technology Patient Engagement

Best Practices in the Use of Digital Technologies within Medical Affairs: Digital Patient Engagement and Emerging Digital Trends in Medical Affairs

ID: 5647


Features:

9 Info Graphics

15 Data Graphics

270+ Metrics


Pages/Slides: 33


Published: 2020


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Best Practices in the use of Digital Technologies within Medical Affairs: Digital Patient Engagement and Emerging Digital Trends in Medical Affairs”

STUDY OVERVIEW

Digitization is transforming the way Medical Affairs engages with key influential stakeholders. Consequently, many organizations are enhancing their Medical Affairs function’s digital capabilities to significantly impact their key operations and improve the effectiveness of their patient engagement programs.

Best Practices, LLC conducted this benchmarking research to probe the use of digital technologies within Medical Affairs. The study provides benchmarks around patient engagement through e-medical initiatives and highlights key emerging trends and digital issues in Medical Affairs.

Insights in this study are further presented into three different segments: Digital Leaders; Digital Majority; and Digital Laggards.

KEY TOPICS

  • Digital Initiative in Medical Affairs
  • Empowering Patients through e-Medical Initiatives
  • Key Trends and Emerging Digital Issues in Medical Affairs

KEY METRICS
  • Where would you say your digital patient engagement program currently stands on an overall maturity curve?
  • Which digital channels does your Medical Affairs function currently use to engage with patients and how effective are these?
  • How effective are your previously-selected digital channels for driving better overall engagement with patients?
  • How important are the listed drivers in successfully engaging patients in a digital manner?

SAMPLE KEY FINDINGS
  • Empowering Patients through e-Medical Initiatives: Digital efforts around patients are less established than with HCPs and TLs. While a majority of participants serve HCPs and TLs through digital channels, only half have implemented digital patient engagement programs.

METHODOLOGY

Best Practices, LLC engaged 74 executives from 53 leading life sciences companies in this research through a benchmarking survey instrument and interviews. The study insights are mostly from directors and higher management executives, representing nearly 80% of the participants. Insights in this research are presented into three different segments to provide deeper insights: Digital Leaders (16 respondents); Digital Majority (38 respondents); and Digital Laggards (20 respondents).


Industries Profiled:
Biotech; Medical Device; Pharmaceutical; Biopharmaceutical; Diagnostic; Health Care; Chemical; Manufacturing; Communications; Clinical Research; Laboratories; Science; Consulting


Companies Profiled:
Aeglea BioTherapeutics; Alcon; Alexion Pharmaceuticals; Alkermes; Alnylam Pharmaceuticals; Astellas; AstraZeneca; BioDelivery Sciences International; Inc.; Biodesix; bioMerieux; Boehringer Ingelheim; Eisai; Eli Lilly and Company; EMD Serono; Exelixis ; GE Healthcare; Genentech; GRAIL; Grifols; GlaxoSmithKline ; Ipsen; Janssen; Jazz Pharmaceuticals; Julphar; Kedrion Biopharma; Lexicon Pharmaceuticals; Lundbeck; Mallinckrodt; Merck; MyoKardia; Nabriva Therapeutics; NexGen Healthcare Communications; Novartis; Novo Nordisk; Pfizer; Radius Health; Reata Pharmaceuticals; Roche; Sage Therapeutics; Sandoz; Sanofi; Sanofi Genzyme; Santen; Springworks Therapeutics; Sunovion; Takeda Pharmaceuticals; Terumo Corporation; Teva Pharmaceutical Industries Ltd; TG Therapeutics; Thermo Fisher Scientific; UCB Pharma; Vertex Pharmaceuticals; Vynamic

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.